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Abstract.  While pathogenic T cells have been identified for several diseases with epithelial cell damage, an
autoimmune T cell-mediated response targeted against a known keratinocyte antigen has not been reported.
Previously we described an autoimmune response directed to the mouse epidermal cell antigens, Skn.  For
our murine model, primed Skn-immune lymphocytes are adoptively transferred to recipients, which develop
lesions at the site of mild skin trauma.  In this study we investigated the nature of the autoimmune component
of the Skn response. A time-course study demonstrated a relationship between the number of primed Skn-
immune cells injected and the severity of skin lesions in the recipients.  Immunohistochemical staining
revealed the presence of both CD4+ and CD8+ T cells in lesional skin, with a predominance of CD4+ T
cells.  To support a role for CD4+ T cells in the initiation of the autoimmune response, Skn-immune donor
cells were either enriched or depleted of various subsets prior to transfer into recipients, which showed that
CD4+, but not CD8+, T cells were essential for induction of lesions.  Analysis of mRNA for T-helper (Th)
cell cytokines in lesional skin displayed a Th1 bias, and treatment with cyclosporin A (CsA) or anti-interleukin
(IL)-2 antibody controlled the development of lesions.  Overall the results clearly show an immunopathogenic
profile consistent with a T cell-mediated mechanism. (received 13 October 2002, accepted 22 December 2002)
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Introduction
Autoimmune disease in humans is estimated to affect
at least 2% of the population in the United States.
Sometimes, however, immune reactivity can cause
tissue damage without signs that the disease is caused
by a response to self antigen.  We have previously
described an autoimmune response directed to the
skin in mice that targets the self epidermal cell
antigens, Skn [1].
Skn antigens are localized selectively to
epidermal cells [2-4] and neuronal cells [2,5]. They
are encoded by 2 unlinked genes, Skn1 and Skn2
[6], each with alternative alleles expressed as allo-
antigens in various mouse strains [7].  Monoclonal
antibody produced to Skn2 identifies a 95 kD
protein [5] that is likely to have a human equivalent,
since anti-Skn2 antibody recognizes a similar sized
molecule in human epidermal cells (Goldberg and
Rees, personal communication).
Previous work indicates that Skn immunization
of donors is important for the transfer of disease.
Lymphocytes from donors primed to Skn antigens
(referred to as Skn-immune cells) cause lesions in
recipient mice, while lymphocytes from donors
immunized to an irrelevant (non-Skn) antigen do
not [1].  Allelic specificity is demonstrated by the
finding that recipients of Skn-immune cells,
normally tolerant of grafts with either set of Skn
alleles, become able to reject grafts that express the
priming alleles [1].  This indicates that the anti-Skn
response requires Skn-allele-specific autoimmune
cells and does not result from any pretreatment
procedures per se.
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Because many organ-specific autoimmune
diseases of humans are thought to be caused
predominantly by T cells, the aim of this study was
to evaluate more fully the phenotype of the immune
contribution required for initiating Skn auto-
immune pathogenesis.  We found that CD4+ T cells
were essential for the adoptive transfer of Skn
autoimmunity and that the Th-cell cytokine profile
in lesional skin had a Th1 bias . These results were
supported by the finding that treatment with
cyclosporin A (CsA) or anti-interleukin (IL)-2, but
not anti-IL-4, antibody controlled the development
of lesions.
Materials and Methods
The Institutional Animal Care and Use Committee
of Marshall University approved all experiments.
Mice.   Female C57BL/6J (B6), A/J (A), and B6AF1/
J (B6AF1) mice were purchased from The Jackson
Laboratory (Bar Harbor, ME). Mice were housed
in a conventional animal facility.  Sentinel mice were
used to screen for various pathogens and these tests
were consistently negative.
Donor lymphocytes.  Because Skn congenic mice are
not available, hematopoietic radiation chimeras were
produced and immunized as previously described
[1] to induce a specific response to Skn alleles found
on A strain mouse skin (Skn1.1, Skn2.1) and to avoid
a response both to the alternative Skn alleles (Skn1.2,
Skn2.2) and to major histocompatibility complex
(MHC) antigens. Spleen cells from these chimeras
were used as the source of donor anti-Skn
lymphocytes (Skn-immune cells) for adoptive
transfer into B6AF1 recipients.
Pretreatment of recipients before adoptive cell
transfer. As previously described [1], B6AF1
recipients (age 4-8 mo) were pretreated with mild
epidermal trauma by shaving, and with immuno-
suppression by an iv injection of cyclophosphamide
(200 mg/kg body wt, NEOSAR, Adria Laboratories,
Columbus, OH).  Epidermal trauma was performed
one day (day -1) and immunosuppression was
delivered 4 hr before adoptive cell transfer (day 0).
Adoptive cell transfer and evaluation of lesions. As
previously described [1], spleen cells from immun-
ized chimeras (Skn-immune cells) were dispersed
into a single cell suspension, washed, and adjusted
to the appropriate cell number in PBS.  B6AF1
recipients received the designated number of Skn-
immune cells delivered iv in 0.2 ml PBS (day 0).
Control B6AF1 recipients received spleen cells from
syngeneic B6AF1 donors (naive spleen cells) or were
not injected with cells; both groups of control
animals showed identical results.
All recipients were examined daily for gross
cutaneous lesions and a clinical score was given on a
scale of 0-5 as follows: 1 = shiny patches; 2 = shiny
patches with scaling; 3 = crusts and/or erythema,
area affected covering <50% of shaved area; 4  =
similar to grade 3, area affected >50% but less than
total shaved area; 5 = similar to grade 3, area affected
covering total shaved area.
Two persons, one of whom was unaware of the
specific treatment, examined the mice for lesions.
At various times after cell transfer, skin sections were
stained with hematoxylin and eosin and histo-
pathology was analyzed in a blinded fashion by a
dermatologist and a pathologist, who each evaluated
slides from 6-10 experimental mice and 5-6 controls
at the specified time points.
Immunohistochemistry.   Skin tissue was stained as
previously described [8], except that methyl green
was used as a counterstain.  Primary antibodies were
rat anti-CD4 (clone GK1.5) and rat anti-CD8
(clone 53-6.7), purchased from BD Biosciences (San
Diego, CA).  Tissue sections used as control samples
were treated with PBS instead of the primary
antibody and gave negative results. Two of the co-
authors independently evaluated each slide.
Immunomagnetic separation of T cells.  Spleen cells
from immunized chimeras were separated into
lymphocyte subsets by immunomagnetic separation
using streptavidin-coated BioMag beads (Advanced
Magnetics, Cambridge, MA).  Single cell suspen-
sions were incubated with saturating concentrations
of rat anti-CD4 or rat anti-CD8 (clones as above)
for 30 min at 4°C, washed, and then incubated with
biotinylated-anti-rat IgG (Vector  Laboratories,
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Burlingame, CA) for 30 min.  After washing, the
cells were incubated with BioMag beads for 1 hr at
4°C (70 beads/target cell).
For negatively selected cells, the antibody-coated
population was removed by exposing the cell
suspension to a magnetic field (BioMag Separator,
Advanced Magnetics) and the non-bound cells were
eluted.  For positively selected cells, the bound cells
were collected and the BioMag beads were removed
by culturing the cells overnight in RPMI 1640
supplemented with 10% fetal calf serum, 1%
nonessential amino acids, 20 mM HEPES, 2 mM
L-glutamine, 100 U/ml penicillin, 100 µg/ml
streptomycin sulfate, and 0.1 mM Na pyruvate (Life
Technologies Inc., Rockville, MD).
Purity of depleted or enriched T cell populations
was verified by flow cytometry after staining the cells
with FITC-conjugated anti-CD8 and PE-
conjugated anti-CD4 mAbs (Caltag Laboratories,
San Francisco, CA).
RNA extraction and RT-PCR.  Tissues were
homogenized with a Tekmar SDT Tissumizer
(Tekman, Cincinnati, OH) and total cellular RNA
was extracted using a Micro-Scale Total RNA
Separator Kit (Clontech Laboratories, Palo Alto, CA)
or with TRIzol Reagent (Life Technologies Inc.)
according to the manufacturer’s instructions.  RNA
was stored at -70°C.
cDNA was synthesized from 1 µg total RNA as
previously described [8].  Five microliter aliquots of
the cDNA reaction products were amplified by PCR
for 35 cycles as previously described [8].
PCR products were analyzed by electrophoresis
on 3% NuSieve/1% SeaKem (FMC Bioproducts,
Rockland, ME) agarose gels and visualized by
ethidium bromide staining. Optical densities of the
bands were obtained from scanned prints or directly
from stained gels using the EDAS 120 System
(Eastman Kodak Co., Rochester, NY).  The relative
level for each cytokine was calculated as OD260 for
the cytokine band ÷ OD260 for a β-actin band.
Primers were purchased from Clontech Lab or
synthesized at our institution’s DNA Core Facility.
In vivo administration of monoclonal antibody
(mAb) or cyclosporin A (CsA).  The mAbs to
cytokines were delivered by ip injection at 20 µg/
day in PBS on days 1 to 6 after the adoptive transfer
of Skn-immune cells.  The total dose given to each
animal was chosen from a study that reported an
enhanced T cell-mediated response in a time period
similar to the anti-Skn response [9].  Control animals
received an equivalent volume of PBS.
CsA was prepared in olive oil and injected ip
(10 mg/kg body wt/day) on the specified days.
Control mice received an equal volume of olive oil.
Because all control reagents gave similar results, the
data have been combined.  Purified rat anti-mouse
IL-2 and IL-4 mAbs (clone S4B6 or 11B11,
respectively, without stabilizers or preservatives) were
purchased from BD Biosciences/PharMingen Co
(San Diego, CA).  Cyclosporin A was a product of
Novartis Pharmaceuticals Corp (East Hanover, NJ).
Statistics.  Data for cytokine mRNA were analyzed
by the Mann-Whitney rank sum test or the paired
t-test. In vivo treatments were compared by the non-
paired t-test.  Significance was defined as p <0.05.
Results
Donor Skn-immune cells have a controlling role in
the development of autoimmune skin lesions.  To
demonstrate that Skn-immune cells have a role in
directing the autoimmune response, various doses
of transferred Skn-immune lymphocytes were
injected and the time-course of lesion development
and severity was followed.  As shown in Fig. 1, the
increasing mean clinical scores over time generally
correlated with the number of autoimmune cells
transferred, while animals injected with 100 x106
naive B6AF1 spleen cells did not form lesions (data
not shown).
On days 10 and 13 post transfer, clinical scores
were significantly different for animals receiving the
highest and lowest transfer inocula.  For subsequent
experiments, a dose of 50 x106 Skn-immune cells
was used, because, with minor exceptions (<1%),
all mice developed lesions in the shaved area of skin
and the daily progression of lesion formation could
easily be monitored.  In these animals, scaly lesions
appeared by days 4 to 6 post-transfer, with erythema
and crusts around days 8 to 10 (Fig. 2a).
Immunopathogenesis of Skn autoimmunity
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Fig. 1.  Severity of lesions correlates with the number of
Skn-immune cells transferred.  Recipient mice pretreated
by shaving and immunosuppression with cyclophosph-
amide were injected iv with different doses of  Skn-
immune cells.  The clinical scores of recipients were
recorded for the days indicated.  Results are reported as
mean ± SE of groups of 6-13 mice per time point and
are combined data from 5 experiments
Fig. 2.  Lesions in mice receiving Skn-immune cells.  Recipient mice, pretreated by shaving and immunosuppression
with cyclophosphamide and injected with 50x106 Skn-immune cells, develop lesions confined to the shaved portion
of skin.  (Panel a) A representative mouse at clinical score 4 depicts the erythema and crusts that develop in the shaved
area. (Panel b) H&E-stained section of clinical score 4 shows epidermal alterations (A, acanthosis; P, parakeratosis; U,
ulcer),  thickened dermis (D), and inflammatory infiltrate (I).  (Panel c) The skin of mice pretreated but not injected
with Skn-immune cells was normal.  Scale bar = 50 µm.
Annals of Clinical & Laboratory Science
Microscopic examination of lesional skin
revealed various epidermal abnormalities, including
hyperkeratosis, parakeratosis, and progressive
acanthosis. Most mice with lesions that scored ≥ 3+
had pusular scale crusts and/or areas of ulceration, a
thickened dermal layer, and the presence of leuko-
cytic infiltrates mainly in the dermis and subcutis
(Fig. 2b).  The infiltrates consisted of polymorpho-
nuclear and mononuclear cells.  In contrast,
cutaneous alteration and a cellular infiltrate were
not observed in controls that had undergone the
pretreatment conditions of shaving plus single-dose
immunosuppression with cyclophosphamide, but
were not injected with Skn-immune cells (Fig. 2c).
CD4+ T cells predominate in skin lesions.  Immuno-
histochemical analysis was performed to determine
the presence and phenotype of T cells in the cellular
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infiltrate of mice with lesions.  Areas of shaved skin,
stained with antibody directed to CD4 or CD8
antigens, showed that the T cell population in the
epidermis and dermis consisted mainly of CD4+ T
cells (Fig. 3a).  In comparison, fewer CD8+ T cells
were found in the infiltrate (Fig. 3b).  Neither CD4+
(Fig. 3c) nor CD8+ (not shown) T cells were
observed in the skin of controls that did not receive
Skn-immune cells.  The large number of infiltrating
CD4+ T cells suggested that CD4+ T cells have a
major role in Skn-induced autoimmunity.
CD4+ T  Skn-immune lymphocytes are able to
adoptively transfer anti-Skn autoimmunity. To
better define the T cell phenotype(s) that were
essential for the adoptive transfer of anti-Skn
immunity, Skn-immune spleen cells were depleted
of, or enriched for, CD4+ or CD8+ T cells.
Fig. 3.  CD4+ T cells predominate in Skn-induced skin lesions.  Cryostat sections of lesional skin from mice treated
as described in Fig. 2 were immunostained for the localization of CD4+ (Panel a) or CD8+  (Panel b) T cells, which
are identified as darkly stained cells.  Arrows point to representative cells.  (Panel c) CD4+ T cells were not found in
mice pretreated by shaving and cyclophosphamide, but not injected with Skn-immune cells. Images are representative
of 6 mice from 3 experiments at days 5-11 after cell transfer. Counterstained with methyl green, which stains cell
nuclei.  Scale bar = 50 µm.
Depletion of CD4+ T cells from the Skn-immune
donor population eliminated the ability of the
remaining cells to transfer Skn immunity (Table 1).
In contrast, depletion of CD8+ T cells did not
abrogate the development of lesions.  Likewise
enriched CD4+, but not CD8+, T cells were capable
of transferring disease (Table 1).  The mean scores
of lesions found for unfractionated versus CD8-
depleted or CD4-enriched T cells were not
statistically different.  In general, these results
implied that CD4+ T cells are the main effector cells
for the induction of Skn autoimmunity.  The role
for CD8+ T cells is presently unknown.
T-helper-1 cell cytokine mRNA profiles in skin
lesions. The local immune response resulting from
the adoptive transfer of Skn-immune cells was
analyzed for cytokine transcripts using RNA isolated
Immunopathogenesis of Skn autoimmunity
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from shaved skin at various times after the transfer
process.  Shaved skin was utilized since all recipients
of Skn-immune cells eventually develop gross lesions
at this location [1].  The mRNAs for cytokines
representative of Th1 (IL-2 and interferon (IFN)-γ)
and Th2 (IL-4) CD4+ T cells were analyzed as well
as the mRNA for β-actin, which was used to
normalize the results among animals.
In prelesional mice, IL-2 and IFN-γ mRNAs,
albeit at extremely low levels, were observed in
recipients of  Skn-immune cells while IL-4 mRNA
was not detected in most animals (Fig. 4).  When
clinical scores of 1-2 were found,  mRNA expression
for all cytokines was significantly increased. With
mice exhibiting lesion scores of 3-5, IFN-γ and IL-
4 mRNA continued to be significantly increased
relative to prelesional skin with negligible IL-2
mRNA observed (Fig. 4).  While the expression of
Th1 versus Th2 cytokine mRNA profiles was not
mutually exclusive in skin exhibiting gross lesions,
when comparisons were made in individual mice,
IFN-γ levels were significantly higher than IL-4 levels
(p <0.05) with IFN-γ/IL-4 ratios averaging 2.0.
The data suggested that the cytokine environ-
ment in lesional skin had a Th1 bias.  With the
exception of very weak detection of IFN-γ mRNA
in 2 mice, there was no expression of Th cell cytokine
mRNA in the skin of control mice, indicating that
Fig.  4. Cytokine mRNA expression in lesional skin shows
a Th1 bias.  Mice were treated as described in Fig. 2.
Amplified products from RT-PCR assays for IL-2, IFN-
γ, IL-4, and β-actin from prelesional (n = 4) and lesional
skin (n = 6 or 7) were analyzed by densitometric scanning.
Data are shown as relative amounts of cytokine mRNA
by using β-actin levels for normalization among animals.
The values are means ± SD.  * p <0.05 versus prelesional
level of cytokine; ** p <0.05 versus paired IL-4 level from
individual animals.  Data are representative of 2 or 3
independent experiments.
Table 1.  Characterization of effector T cell populations for adoptively transferred Skn autoimmunity in B6AF1
recipients.a
Treatment Cell population Number of Number with Clinical score
transferred recipient mice skin lesions on days 7-12
T cell depletion Unfractionated 7 7 4.3
CD4 depleted 11 0
CD8 depleted 12 12 3.6
T cell enrichment Unfractionated 5 5 3.3
CD4 enriched 4 4 2.9
CD8 enriched 7 0
a Recipients were shaved, pretreated with 200 mg/kg cyclophosphamide, and given 50 x106 unfractionated or depleted,
or 10 x106 enriched, Skn-immune cells iv.  The results are combined data from 2 or 3 independent experiments,
except for the CD4-enriched data, where all mice were from 1 experiment.
Annals of Clinical & Laboratory Science
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the pretreatment regimen alone was not conducive
to the appearance of Th cytokine mRNA (data not
shown).
Treatment with cyclosporin A (CsA) or anti-IL-2
antibody improves disease course.  Because both Th1
and Th2 mRNA were found early in the course of
Skn-induced autoimmune disease, the effect of
treating recipients of Skn-immune cells with reagents
that would interfere with the expression or function
of representative cytokines was investigated.  CsA
or anti-cytokine antibody was used for these experi-
ments. Recipients were pre-treated in the usual
manner and injected with Skn-immune cells.  CsA
treatment by daily ip injection was administered
either from day 1 to 14 post-transfer of Skn-immune
cells or was started at the onset of gross lesions and
continued thereafter for 10 days.  When the results
of both methods of treatment with CsA were
combined, these treatment significantly reduced the
disease severity in that 5 of 6 recipients did not
develop lesions with a clinical score >1 (Table 2; p
<0.05 versus control reagents).  However, because
the number of animals was small and one mouse
did not respond to CsA treatment, these data were
interpreted cautiously.   Likewise, anti-IL-2
treatment, where antibody was delivered from day
1 to 6 post-transfer of Skn-immune cells, also caused
a notable abatement in lesion severity in all recipients
(Table 2), with lesion scores limited to 1 (p <0.05
versus control reagents).  However, recipients that
received anti-IL-4 antibody developed lesions
comparable to those of mice injected with control
reagents.
The persistence of lesions with anti-IL-4
treatment also served to show that antibody
treatment per se could not affect lesion control.
Animals were observed for 25 days and in no case
did any recipients develop lesions of increased
severity after the termination of CsA or anti-IL-2
treatment.  Although the number of animals  in these
experiments was minimal, the data support the
CD4+ and Th1 bias found in lesional skin.
Discussion
Using a mouse model, we previously reported an
autoimmune response to the epidermal cell antigens,
Skn [1], and in this report have supported the anti-
self specificity of the response by demonstrating that
the severity of the clinical response generally
correlated with the injected dose of primed Skn
immune cells transferred to recipients.  We then set
out to evaluate the role of CD4+ T cells in the Skn
response.
Table 2.  Effect of in vivo treatments with CsA, anti-IL-2, or anti-IL-4 antibody on the development of Skn-induced
lesions.a
Clinical score of lesionsb
Number of Mice Reagent no lesion 1 2 3 4 5
6 CsAc 0     5d,e 0 0 1d 0
4 Anti-IL-2c 1 3 0 0 0 0
4 Anti-IL-4 0 0 1 1 2 0
4 Control reagent f 0 0 0 2 2 0
a B6AF1 recipients were shaved, injected with cyclophosphamide, and given 50x106 Skn-immune  spleen cells.
b At days 12-14 post-transfer.
c p <0.05 versus control reagents.
d Delivered day 1-14 post transfer of Skn-immune cells, n = 3.
e Delivered at lesion onset and thereafter for 10 days, n = 3.
f Control reagents were either PBS (diluent for antibodies) or olive oil (vehicle for CsA).
Immunopathogenesis of Skn autoimmunity
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In our model, staining of lesional skin with
antibody for CD4 and CD8 revealed the presence
of both types of T cells with the former as the
predominant phenotype.  The large number of
CD4+ cells present implied that these cells probably
have a role in initiating the pathogenic process. This
inference was substantiated, in that transferred Skn-
immune cells enriched for CD4 but not CD8 could
elicit lesions in recipient mice. Likewise, when CD4+
T cells were removed from the transferred inoculum,
lesions did not develop.
Several dermatological diseases with chronic
etiology appear to have a cell-mediated autoimmune
component, although the inciting self antigens have
not yet been identified [10].  Mixed CD4/CD8
infiltrates are reported in lesions from patients with
lichen planus [11-13], alopecia areata [14], vitiligo
[15,16], and psoriasis [17-19].  While lesional
appearance of defined cell types does not necessarily
imply disease-activating characteristics, a pivitol role
for CD4+ T cells has been demonstrated for
pathogenesis in animal models of vitiligo [20],
psoriasis [21,22], and alopecia aerata [23].  Our
results are consistent with the findings from putative
autoimmune human skin diseases and strongly
suggest that CD4+ cells are preferentially required
for initiation of  Skn-targeted autoreactivity,
although the data do not exclude the possibility that
CD8+ cells contribute to the process.
When autoimmune disease was studied in the
context of T-helper (Th) cytokines, it was shown
that organ-specific autoimmunity is often associated
with cytokines that favor the inflammatory Th1 type
[24].   Skn skin lesions were evaluated for prototypic
cytokine mRNA that defined Th1 (IL-2, IFN-γ) and
Th2 (IL-4) subsets, revealing a bias toward a Th1
environment.  Moreover, treatment with anti-IL-2,
but not anti-IL-4, antibody significantly improved
the autoimmune anti-Skn disease outcome, which
reinforced the role of Th1 cytokines in the
pathogenic process.  A similar partiality toward Th1
is observed in active lesions from patients with
alopecia areata [25] and vitiligo [26].  Psoriatic
patients also show a predominance toward the Th1
cytokine pattern [27-30], although some studies
have indicated random Th profiles [31,32] similar
to that reported for lichen planus [33].
Immunosuppressive drugs are often used in the
treatment of diseases with chronic immune-based
pathology.  Skn-lesion severity was clearly reduced
by cyclosporin therapy and is consistent with this
drug’s effect against cell-mediated immune
responses.
In summary, we have shown that the pathology
induced to self epidermal cell antigens has the
immune characteristics associated with a CD4+ T
cell-mediated response.  However, the presence of
autoantigen together with autoreactive lymphocytes
is often insufficient to precipitate clinical disease,
indicating that other factors contribute to
pathognensis.  In our model, lesions form only in
areas stressed by shaving, suggestive of the Koebner
phenomenon, a condition in certain skin disorders
wherein lesions appear at the site of trauma.  We are
currently evaluating what additional conditions
within the skin and the skin’s resident immune
system contribute to the local tissue environment
that is conducive to lesion formation.
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